MPLT - Public offerings

Topline results from Phase 2 ZEPHYR trial of ML-007C-MA for schizophrenia expected in the second half of 2026Topline results from Phase 2 VISTA trial of ML-007C-MA for Alzheimer's disease psychosis expected in the second half of 2027Raised $296.5 million in gross proceeds from initial public offering and concurrent private placement completed in October 2025Cash, cash equivalents and short-term investments sufficient to fund operations through 2027 SAN FRANCISCO and BOSTON, Dec. 04, 2025 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (NASDAQ:MPLT), a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system diso

SAN FRANCISCO and BOSTON, Oct. 29, 2025 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system disorders, today announced the closing of its initial public offering of 16,962,500 shares of common stock at an initial public offering price of $17.00 per share, which includes the exercise in full by the underwriters of their option to purchase an additional 2,212,500 shares of common stock. In addition to the shares sold in the initial public offering, MapLight announced the closing of the concurrent sale of 476,707 shares of common stock at the initial public of